scispace - formally typeset
Search or ask a question
Institution

University of Kansas

EducationLawrence, Kansas, United States
About: University of Kansas is a education organization based out in Lawrence, Kansas, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 38183 authors who have published 81381 publications receiving 2986312 citations. The organization is also known as: KU & Univ of Kansas.


Papers
More filters
Journal ArticleDOI
TL;DR: Preliminary results from this trial define the prevalence and incidence of dysplasia and cancer in a multicenter cohort of patients with Barrett's esophagus and evaluate the paths of progression in a large multicenter cohorts of BE patients.

382 citations

Journal ArticleDOI
TL;DR: Reassessment of evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy finds it highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine.
Abstract: Objective: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy. Methods: Systematic review of relevant articles published between January 1985 and June 2007. Results: It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine. Compared to untreated WWE, it is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. It is probable that antiepileptic drug (AED) polytherapy as compared to monotherapy regimens contributes to the development of MCMs and to reduced cognitive outcomes. For monotherapy, intrauterine exposure to VPA probably reduces cognitive outcomes. Further, monotherapy exposure to phenytoin or phenobarbital possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of <7. Recommendations: If possible, avoidance of valproate (VPA) and antiepileptic drug (AED) polytherapy during the first trimester of pregnancy should be considered to decrease the risk of major congenital malformations (Level B). If possible, avoidance of VPA and AED polytherapy throughout pregnancy should be considered to prevent reduced cognitive outcomes (Level B). If possible, avoidance of phenytoin and phenobarbital during pregnancy may be considered to prevent reduced cognitive outcomes (Level C). Pregnancy risk stratification should reflect that the offspring of women with epilepsy taking AEDs are probably at increased risk for being small for gestational age (Level B) and possibly at increased risk of 1-minute Apgar scores of <7 (Level C).

382 citations

Journal ArticleDOI
TL;DR: A clinical scheme for approaching the chronic acquired demyelinating polyneuropathies that leads to a rational use of supportive laboratory studies and treatment options is described and new diagnostic criteria for CIDP are proposed that more accurately reflect current clinical practice.
Abstract: A number of presentations of chronic demyelinating polyneuropathy have been identified, each distinguished by its phenotypic pattern. In addition to classic chronic inflammatory demyelinating polyneuropathy (CIDP), which is characterized clinically by symmetric proximal and distal weakness and sensory loss, several regional variants can be recognized: multifocal motor neuropathy (MMN: asymmetric and pure motor), multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy (asymmetric, sensory, and motor), and distal acquired demyelinating symmetric (DADS) neuropathy (symmetric, distal, sensory, and motor). There are also temporal, pathological, and disease-associated variants. This review describes a clinical scheme for approaching the chronic acquired demyelinating polyneuropathies that leads to a rational use of supportive laboratory studies and treatment options. In addition, we propose new diagnostic criteria for CIDP that more accurately reflect current clinical practice.

382 citations

Journal ArticleDOI
06 Feb 2019-PeerJ
TL;DR: The kuenm R package is presented, a new set of tools for performing detailed development of ecological niche models using the platform Maxent in a reproducible way, and allows robust processes of model calibration, facilitating creation of final models based on model significance, performance, and simplicity.
Abstract: Background Ecological niche modeling is a set of analytical tools with applications in diverse disciplines, yet creating these models rigorously is now a challenging task. The calibration phase of these models is critical, but despite recent attempts at providing tools for performing this step, adequate detail is still missing. Here, we present the kuenm R package, a new set of tools for performing detailed development of ecological niche models using the platform Maxent in a reproducible way. Results This package takes advantage of the versatility of R and Maxent to enable detailed model calibration and selection, final model creation and evaluation, and extrapolation risk analysis. Best parameters for modeling are selected considering (1) statistical significance, (2) predictive power, and (3) model complexity. For final models, we enable multiple parameter sets and model transfers, making processing simpler. Users can also evaluate extrapolation risk in model transfers via mobility-oriented parity (MOP) metric. Discussion Use of this package allows robust processes of model calibration, facilitating creation of final models based on model significance, performance, and simplicity. Model transfers to multiple scenarios, also facilitated in this package, significantly reduce time invested in performing these tasks. Finally, efficient assessments of strict-extrapolation risks in model transfers via the MOP and MESS metrics help to prevent overinterpretation in model outcomes.

382 citations

Journal ArticleDOI
TL;DR: To evaluate fibromyalgia in the general population with emphasis on prevalence, dimensionality, and somatic symptom severity.
Abstract: Objective To evaluate fibromyalgia in the general population with emphasis on prevalence, dimensionality, and somatic symptom severity. Methods We studied 2,445 subjects randomly selected from the German general population in 2012 using the American College of Rheumatology 2010 preliminary diagnostic criteria for fibromyalgia, as modified for survey research, and the polysymptomatic distress scale (PSD). Anxiety, depression, and somatic symptom severity were assessed with the Patient Health Questionnaire (PHQ) series, and measures of symptoms and quality of life were assessed with the European Organization for Research and Treatment of Cancer questionnaire. Results The prevalence of fibromyalgia was 2.1% (95% confidence interval [95% CI] 1.6, 2.7), with 2.4% (95% CI 1.5, 3.2) in women and 1.8% (95% CI 1.1, 2.6) in men, but the difference was not statistically significant. Prevalence rose with age. Fibromyalgia subjects had markedly abnormal scores for all covariates. We found smooth, nondisordered relationships between PSD and all predictors, providing additional evidence against the hypothesis that fibromyalgia is a discrete disorder and in support of a dimensional or spectrum disorder. There was a strong correlation (r = 0.790) between the PSD and the PHQ somatic symptom severity scale; 38.5% of persons with fibromyalgia satisfied the proposed Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for a physical symptom disorder. Conclusion The modified 2010 diagnostic criteria do not result in high levels of fibromyalgia. PSD and fibromyalgia are strongly related to somatic symptom severity. There is evidence in support of fibromyalgia as a dimensional or continuum disorder. This has important ramifications for neurobiologic and epidemiology research, and for clinical diagnosis, treatment, and ascertainment of disability.

381 citations


Authors

Showing all 38401 results

NameH-indexPapersCitations
Gordon H. Guyatt2311620228631
Krzysztof Matyjaszewski1691431128585
Wei Li1581855124748
David Tilman158340149473
Tomas Hökfelt158103395979
Pete Smith1562464138819
Daniel J. Rader1551026107408
Melody A. Swartz1481304103753
Kevin Murphy146728120475
Carlo Rovelli1461502103550
Stephen Sanders1451385105943
Marco Zanetti1451439104610
Andrei Gritsan1431531135398
Gunther Roland1411471100681
Joseph T. Hupp14173182647
Network Information
Related Institutions (5)
University of Minnesota
257.9K papers, 11.9M citations

96% related

Yale University
220.6K papers, 12.8M citations

95% related

University of Washington
305.5K papers, 17.7M citations

95% related

Duke University
200.3K papers, 10.7M citations

95% related

University of Michigan
342.3K papers, 17.6M citations

94% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202391
2022358
20214,211
20204,204
20193,766
20183,485